June 27th 2025. The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening ...

In this interview, Patrick Soon-Shiong, MD, shares key updates in the development of nogapendekin alfa inbakicept-pmln (Anktiva), which was approved by the FDA in April 2024 for patients with ...

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

In this interview, Arpeet Shah, MD, considers some of the advancements and challenges that the field of urology will face in the coming year.Shah is a urologist at Associated Urological Specialists, ...

In this interview, Nedim Ruhotina, MD, outlines currently available as well as promising up-and-coming biomarkers for advanced prostate cancer. Dr Ruhotina is a urologist with Associated Medical ...

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

We identify a statistically higher odds of urethral stricture, genital numbness, and saddle sores (OR: 9.8, p<.001) in cyclists compared to swimmers/runners.Several other large studies corroborate ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

Bladder cancer is the 10th most common cancer worldwide with an estimated 82,000 new diagnoses and 17,000 deaths in 2023. 1 The majority of patients present with non–muscle invasive bladder cancer ...

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%. The EpiSwitch Prostate Screening (PSE) blood test has been clinically validated and is now available ...

The investigational HIF-2α inhibitor casdatifan has shown early promise in terms of clinical activity and was also found to be well tolerated in patients with previously treated clear cell renal cell ...